Multicenter, USA - 20 Sep `19Incyte: Ruxolitinib cream (TRuE-V1)

Official Title: Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1): A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo.

In Brief: Participants will receive ruxolitinib cream or placebo for 24 weeks, after which they will be offered the opportunity to continue in the treatment extension period. Participants initially randomized to placebo will be crossed over to active drug, and participants treated with ruxolitinib cream will receive an additional 28 weeks of treatment with ruxolitinib cream.

Details: For a plain language details check Incyte announcement or download pdf of a scientific presentation from UMass.

Ages eligible: 12 Years and older 

Locations

  • Center For Dermatology and Plastic Surgery: Scottsdale, Arizona, United States, 85260
  • Burke Pharmaceutical Research: Hot Springs, Arkansas, United States, 71913
  • Marvel Clinical Research: Huntington Beach, California, United States, 92647
  • Rady Children's Hospital: San Diego, California, United States, 92123
  • Clinical Research Center of Connecticut: Danbury, Connecticut, United States, 06810
  • Harmony Medical Research Institute: Hialeah, Florida, United States, 33016
  • San Marcus Research Clinic: Miami Lakes, Florida, United States, 33014
  • ForCare Medical Center: Tampa, Florida, United States, 33613
  • Metabolic Research Institute: West Palm Beach, Florida, United States, 33401
  • Northwestern University, Chicago, Illinois, United States, 60611
  • Great Lakes Research Group: Bay City, Michigan, United States, 48706
  • Washington University in St Louis: Saint Louis, Missouri, United States, 63141
  • SUNY Downstate Medical Center: Brooklyn, New York, United States, 11203
  • Forest Hills Dermatology Group: Forest Hills, New York, United States, 11375
  • Buka Dermatology: New York, New York, United States, 10012
  • M3 Wake Research: Raleigh, North Carolina, United States, 27612
  • Wake Forest University Health Sciences: Winston-Salem, North Carolina, United States, 27157
  • KGL Skin Study Center: Broomall, Pennsylvania, United States, 19008
  • Dermatology Associates of Plymouth Meeting: PC Plymouth Meeting, Pennsylvania, United States, 19462
  • Palmetto Clinical Trial Services: Anderson, South Carolina, United States, 29621
  • International Clinical Research-Tennessee: Murfreesboro, Tennessee, United States, 37130
  • Progressive Clinical Research - San Antonio: San Antonio, Texas, United States, 78213
  • Dermatology Clinical Research Center of San Antonio; San Antonio, Texas, United States, 78229
  • Dermatology Specialists of Spokane: Spokane, Washington, United States, 99202

Status: Active, recruiting

Start date: September 20, 2019
Completion date (estimated): November 30, 2021

ClinicalTrials.gov identifier: NCT04052425

Contacts: To learn more about this study, you or your doctor may contact Incyte Corporation Call Center by phone +800 00027423 or email globalmedinfo@incyte.com. Please refer to this study by its NCT number.

 

FAQOther Questions

  • What tests should be done?

    A well-trained dermatologist should be able to diagnose vitiligo and distinguish it from contact leukoderma or more than twenty other conditions with similar skin appearance bas...

  • What's better: laser or phototherapy?

    In a recent study researchers assessed effect and safety of different laser and phototherapy treatments, such as excimer laser/light, narrowband UVB, UVA and PUVA. No significa...

  • How can I cure vitiligo?

    There is no cure for vitiligo, but there are a number of effective treatment options that can be discussed with your GP or dermatologist. The aim of treatment is to stop new pat...